◼ Archived
Health
🔮 fades ✓
Genetically modified pig kidney keeps man alive for record nine months
A patient survives a record 271 days with a gene-edited pig kidney before receiving a human transplant.
Gene Editing
9 trends tracked about this subject — the full history, oldest to newest below.
◼ Archived
World
🔮 fades ✓
Gene-Editing Technology Offers New Ways to Create the Dogs of Our Dreams
Recent breakthroughs in CRISPR gene-editing technology have enabled the creation of hypoallergenic beagles, offering a new option for allergy sufferers.
◼ Archived
Science
🔮 fades ✓
Scientist uses gene-editing to breed dog that won’t trigger his allergies
A scientist has employed gene-editing techniques to breed a dog designed specifically to avoid triggering his own personal pet allergies.
◼ Archived
Science
🔮 fades ✗
Gene-edited beagles may offer a future option for people with dog allergies
Kindred Companion Sciences has used CRISPR gene-editing to create hypoallergenic beagles by removing a major allergy-causing protein.
◼ Archived
Health
🔮 fades ✓
Journal, university investigations launched into gene-editing death following Science-Retraction Watch reporting
Investigations are underway following a child's death in a gene-editing trial, flagged by Science-Retraction Watch reporting.
◼ Archived
Health
🔮 fades ✗
CRISPR makes prostate cancer vulnerable to immunotherapy
6 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
◼ Archived
Health
🔮 fades ✓
Girl died after gene-editing treatment in China: Report
A Chinese scientist faces an official probe following reports that a young girl died after undergoing an experimental gene-editing treatment.
◼ Archived
Health
🔮 fades
Exclusive: A couple paid more than $800,000 for a gene-editing therapy for their daughter. She died, and it wasn’t made public
A secret death in a Chinese gene-editing trial involving a six-year-old girl and an $800,000 payment has sparked a global ethics crisis.
◼ Archived
Business
🔮 fades
Scribe Therapeutics files for IPO in test of public appetite for earlier-stage biotechs
Scribe Therapeutics seeks $75 million in an IPO, testing market appetite for early-stage biotech.